Article ID Journal Published Year Pages File Type
1367521 Bioorganic & Medicinal Chemistry Letters 2006 5 Pages PDF
Abstract

Dipeptidyl peptidase IV is a clinically validated target for type-2 diabetes and belongs to a family of peptidases with a quite unique post-proline cleavage specificity. Known inhibitors contain a limited number of molecular anchors occupying the small prototypical S1 pocket. A virtual screening approach for such S1-binding fragments was carried out using FlexX docking to evaluate its potential to confirm known and find novel compounds. Several low molecular weight inhibitors exhibiting activities in the micromolar range could be identified as starting points for structure-based design.

Graphical abstractA virtual screening approach for S1-binding fragments of dipeptidyl peptidase IV using FlexX-Pharm docking confirmed substructures of known inhibitors and identified novel fragments with activities in the micromolar range suitable as starting points for structure-based design.Figure optionsDownload full-size imageDownload as PowerPoint slide

Related Topics
Physical Sciences and Engineering Chemistry Organic Chemistry
Authors
, , , ,